A
The startup develops a biopharmaceutical therapy specifically targeting ocular surface disease, focusing on dry eye treatment through disease-modifying interventions. This approach provides patients with effective management options for their condition, enhancing their quality of life.
Medfield, United States
Updated 2 months ago
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a biopharmaceutical therapy specifically targeting ocular surface disease, focusing on dry eye treatment through disease-modifying interventions. This approach provides patients with effective management options for their condition, enhancing their quality of life.